NeoGenomics Statistics
Total Valuation
NeoGenomics has a market cap or net worth of $1.95 billion. The enterprise value is $2.19 billion.
Important Dates
The last earnings date was Tuesday, November 5, 2024, before market open.
| Earnings Date | Nov 5, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
NeoGenomics has 128.36 million shares outstanding. The number of shares has increased by 0.92% in one year.
| Current Share Class | 128.36M |
| Shares Outstanding | 128.36M |
| Shares Change (YoY) | +0.92% |
| Shares Change (QoQ) | +0.43% |
| Owned by Insiders (%) | 1.31% |
| Owned by Institutions (%) | 97.41% |
| Float | 126.62M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 97.52 |
| PS Ratio | 3.01 |
| Forward PS | 2.77 |
| PB Ratio | 2.17 |
| P/TBV Ratio | 52.71 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 131.38 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.40 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.99, with a Debt / Equity ratio of 0.67.
| Current Ratio | 1.99 |
| Quick Ratio | 1.82 |
| Debt / Equity | 0.67 |
| Debt / EBITDA | 56.42 |
| Debt / FCF | n/a |
| Interest Coverage | -10.96 |
Financial Efficiency
Return on equity (ROE) is -8.38% and return on invested capital (ROIC) is -2.98%.
| Return on Equity (ROE) | -8.38% |
| Return on Assets (ROA) | -2.76% |
| Return on Capital (ROIC) | -2.98% |
| Revenue Per Employee | $306,723 |
| Profits Per Employee | -$37,013 |
| Employee Count | 2,100 |
| Asset Turnover | 0.39 |
| Inventory Turnover | 14.99 |
Taxes
| Income Tax | -2.11M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -20.87% in the last 52 weeks. The beta is 1.18, so NeoGenomics's price volatility has been higher than the market average.
| Beta (5Y) | 1.18 |
| 52-Week Price Change | -20.87% |
| 50-Day Moving Average | 14.65 |
| 200-Day Moving Average | 14.87 |
| Relative Strength Index (RSI) | 56.13 |
| Average Volume (20 Days) | 751,978 |
Short Selling Information
| Short Interest | 4.24M |
| Short Previous Month | 4.63M |
| Short % of Shares Out | 3.30% |
| Short % of Float | 3.35% |
| Short Ratio (days to cover) | 5.29 |
Income Statement
In the last 12 months, NeoGenomics had revenue of $644.12 million and -$77.73 million in losses. Loss per share was -$0.62.
| Revenue | 644.12M |
| Gross Profit | 280.43M |
| Operating Income | -73.17M |
| Pretax Income | -83.44M |
| Net Income | -77.73M |
| EBITDA | -447,000 |
| EBIT | -73.17M |
| Loss Per Share | -$0.62 |
Full Income StatementBalance Sheet
The company has $387.81 million in cash and $606.27 million in debt, giving a net cash position of -$218.46 million or -$1.70 per share.
| Cash & Cash Equivalents | 387.81M |
| Total Debt | 606.27M |
| Net Cash | -218.46M |
| Net Cash Per Share | -$1.70 |
| Equity (Book Value) | 908.21M |
| Book Value Per Share | 7.09 |
| Working Capital | 293.84M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $15.01 million and capital expenditures -$36.52 million, giving a free cash flow of -$21.51 million.
| Operating Cash Flow | 15.01M |
| Capital Expenditures | -36.52M |
| Free Cash Flow | -21.51M |
| FCF Per Share | -$0.17 |
Full Cash Flow StatementMargins
Gross margin is 43.54%, with operating and profit margins of -11.36% and -12.07%.
| Gross Margin | 43.54% |
| Operating Margin | -11.36% |
| Pretax Margin | -12.39% |
| Profit Margin | -12.07% |
| EBITDA Margin | -0.07% |
| EBIT Margin | -11.36% |
| FCF Margin | -4.73% |
Dividends & Yields
NeoGenomics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.92% |
| Shareholder Yield | -0.92% |
| Earnings Yield | -3.94% |
| FCF Yield | -1.09% |
Dividend DetailsAnalyst Forecast
The average price target for NeoGenomics is $20.25, which is 32.96% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $20.25 |
| Price Target Difference | 32.96% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on April 16, 2003. It was a reverse split with a ratio of 0.01:1.
| Last Split Date | Apr 16, 2003 |
| Split Type | Reverse |
| Split Ratio | 0.01:1 |
Scores
NeoGenomics has an Altman Z-Score of 1.81 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.81 |
| Piotroski F-Score | 5 |